Markets Featured

$VSTM: The 50% Response Rate Is Real. So Is the 31% Dilution.

Verastem's KRAS G12D inhibitor posted a 50% confirmed response rate in second-line pancreatic cancer, and the company sold $250 million of new stock on it overnight. The share-count math, the cash clock, and the scenario zones.

Alpha One

14 Oct 2026 • 9 min read

Operated by veterans. Driven by discipline. Built for the early mover.
AlphaBriefing provides financial commentary and market analysis for informational purposes only. We do not offer personalized investment advice. All content is opinion-based and should not be considered a recommendation to buy or sell any security. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal. Individual results may vary. We value your privacy. Any data collected is used to improve your experience and to provide relevant updates about our services.
©2025 AlphaBriefing. All rights reserved. | Privacy Policy | Legal Disclaimer